+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xenazine"

Xenazine - API Insight, 2022 - Product Thumbnail Image

Xenazine - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Xenazine- Drug Insight, 2019 - Product Thumbnail Image

Xenazine- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Xenazine is a drug used to treat tardive dyskinesia, a neurological disorder characterized by involuntary movements. It is a member of the musculoskeletal disorders drugs market, which includes drugs used to treat a variety of conditions such as arthritis, osteoporosis, and fibromyalgia. These drugs are used to reduce pain, improve mobility, and reduce inflammation. Xenazine is a brand name for tetrabenazine, a drug that works by blocking dopamine receptors in the brain. It is used to reduce the severity of tardive dyskinesia symptoms, such as involuntary movements of the face, tongue, and extremities. It is available in tablet form and is taken orally. The musculoskeletal disorders drugs market is highly competitive, with many companies offering products to treat a variety of conditions. Some of the major players in the market include Pfizer, Novartis, Merck, and Johnson & Johnson. Other companies include AbbVie, Amgen, and Bristol-Myers Squibb. Show Less Read more